Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry

American Journal of Hematology

Volumn 92, Issue 7, 2017, Pages 646-652

  Recht, Michael ^a   Rajpurkar, Madhvi ^b   Chitlur, Meera ^b   d'Oiron, Roseline ^c   Zotz, Rainer ^d   Di Minno, Giovanni ^e   Cooper, David L ^f   Poon, Man Chiu ^g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c BICÊTRE HOSPITAL   (France)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f NOVO NORDISK INC   (United States)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE ANTIBODY; ALLOANTIBODY; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; COMBINATION DRUG THERAPY; DENTAL SURGERY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ELECTIVE SURGERY; EMERGENCY SURGERY; ENDOSCOPIC SURGERY; EPISTAXIS; FEMALE; GINGIVA BLEEDING; GLANZMANN DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MENORRHAGIA; MINOR SURGERY; NOSE SURGERY; OBSERVATIONAL STUDY; ORAL BLEEDING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; THROMBOCYTE AGGREGATION; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE; YOUNG ADULT; ADVERSE EFFECTS; COMPLICATION; HEMORRHAGE; IMMUNOLOGY; NEWBORN; PRESCHOOL CHILD; SURGERY; THROMBASTHENIA; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COAGULANTS; DRUG THERAPY, COMBINATION; FACTOR VIIA; FEMALE; HEMORRHAGE; HUMANS; INFANT; INFANT, NEWBORN; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS; SURGICAL PROCEDURES, OPERATIVE; THROMBASTHENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019146252     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24741     Document Type: Article

References (16)

1. Nurden AT, Pillois X, Nurden P. Understanding the genetic basis of Glanzmann thrombasthenia: implications for treatment. Expert Rev Hematol. 2012;5:487–503.
2. Di Minno G, Coppola A, Di Minno MN, et al. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost. 2009;102:1157–1164.
3. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383–1395.
4. Bellucci S, Caen J. Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16:193–202.
5. Spiess BD. Platelet transfusions: the science behind safety, risks and appropriate applications. Best Pract Res Clin Anaesthesiol. 2010;24:65–83.
6. Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia. 2008;14:103–110.
7. Poon MC, d'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2:1096–1103.
8. Rajpurkar M, Chitlur M, Recht M, et al. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia. 2014;20:464–471.
9. Lisman T, Adelmeijer J, Heijnen HF, et al. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood. 2004;103:1720–1727.
10. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101:1864–1870.
11. Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia. Vasc Health Risk Manag. 2007;3:655–664.
12. NovoSeven [Summary of Product Characteristics]. Novo Nordisk A/S, Bagsvaerd, Denmark. July 2013.
13. Di Minno G, Zotz RB, d'Oiron R, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015;100:1031–1037.
14. Poon MC, d'Oiron R, Zotz RB, et al. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica. 2015;100:1038–1044.
15. NovoSeven RT Coagulation Factor VIIa (Recombinant) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2014.
16. Chitlur M, Rajpurkar M, Recht M, et al. Independent adjudicator assessment of efficacy of recombinant factor VIIa in bleeding/surgery in the Glanzmann's thrombasthenia registry (GTR). Haemophilia. 2015;21:e261.